Sangamo Therapeutics, Inc.SGMONASDAQ
LOADING
|||
R&D Expense Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-52.35%
↓ 539% below average
Average (9y)
11.92%
Historical baseline
Range
High:74.76%
Low:-52.35%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| 2024 | -52.35% |
| 2023 | -6.34% |
| 2022 | 8.27% |
| 2021 | 27.77% |
| 2020 | 23.80% |
| 2019 | 27.04% |
| 2018 | 74.76% |
| 2017 | 0.17% |
| 2016 | -2.35% |
| 2015 | 18.42% |